Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

496
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
496
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

358
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
358
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

459
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
459
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

552
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
552
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

575
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
575
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

611
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
611

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Helping Our Patients With Valvular Heart Disease: A Call to Action.

Journal of the American College of Cardiology·2026
Same author

Echoes Beyond E and A: Solving the Mystery of the Third Diastolic Wave.

CASE (Philadelphia, Pa.)·2026
Same author

Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies.

Journal of the American Heart Association·2026
Same author

Myocardial Dysfunction in Primary Mitral Regurgitation: A Review.

JAMA cardiology·2025
Same author

Left ventricular apical aneurysm recurrence in a patient with hypertrophic cardiomyopathy and midventricular obstruction.

JTCVS techniques·2025
Same author

Commentary: Sudden death in competitive student-athletes with hypertrophic cardiomyopathy at a crossroads: Critical views on liberalizing return-to-play eligibility.

Heart rhythm·2025
Same journal

Implantable Cardioverter-Defibrillator in Cardiac Sarcoidosis: A Propensity-Score Matched Analysis.

Current problems in cardiology·2026
Same journal

Arterial Stiffness in Heart Failure with Preserved Ejection Fraction: is this a new Predisposing Factor?

Current problems in cardiology·2026
Same journal

The Future of Cardiovascular Training: Bridging Global Disparities and Building a Hybrid Model for Equity in Care.

Current problems in cardiology·2026
Same journal

Disparities in Healthcare Access and Treatment Outcomes for Patients with Chronic Limb-Threatening Ischemia.

Current problems in cardiology·2026
Same journal

Diagnostic and prognostic value of coronary computed tomography angiography and high-risk plaque assessment in acute coronary syndrome.

Current problems in cardiology·2026
Same journal

Prognostic value of albuminuria in heart failure with preserved ejection fraction: A systematic review.

Current problems in cardiology·2026
See all related articles

Related Experiment Video

Updated: Feb 5, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Hypertrophic cardiomyopathy.

Steve R Ommen1, Rick A Nishimura

  • 1Division of Cardiovascular Diseases and Hypertrophic Cardiomyopathy Clinic, Mayo Clinic, Rochester, Minnesota, USA.

Current Problems in Cardiology
|May 5, 2004
PubMed
Summary
This summary is machine-generated.

Hypertrophic cardiomyopathy, a genetic heart condition, presents diverse symptoms and risks, including sudden death. Understanding its genetic basis and varied presentations is key for effective patient management.

More Related Videos

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Related Experiment Videos

Last Updated: Feb 5, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.2K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) is characterized by myocardial hypertrophy without a known cause.
  • HCM is associated with dynamic left ventricular outflow obstruction and sudden cardiac death risk.
  • Genetic mutations in cardiac sarcomere genes are recognized as the primary cause of HCM.

Purpose of the Study:

  • To highlight the heterogeneity of hypertrophic cardiomyopathy.
  • To underscore the challenges in managing HCM patients.
  • To provide an overview of current understanding and management considerations.

Main Methods:

  • Review of existing literature on hypertrophic cardiomyopathy.
  • Analysis of morphologic and pathophysiological differences.
  • Examination of natural history studies and treatment strategies.

Main Results:

  • HCM exhibits significant heterogeneity in its presentation and progression.
  • Multiple sarcomere gene mutations are implicated in HCM development.
  • Disparate findings across studies complicate management.

Conclusions:

  • Effective management of hypertrophic cardiomyopathy requires addressing its complex heterogeneity.
  • Understanding the genetic underpinnings is crucial for personalized treatment.
  • Ongoing research into natural history and novel therapies is essential.